A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Summary

This is an, open-label, multi-center, three-part phase I trial to evaluate the safety, pharmacokinetics and immunogenicity of SHR-1909 and preliminary anti-tumor efficacy of SHR-1909 in advanced malignant cancer.

Timeline

Start

2022-02-23

Primary completion

2024-03-28

Completion

2024-06-13

Drugs

Indications